Literature DB >> 20179498

Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener.

Carsten Bantel1, Mervyn Maze, Stefan Trapp.   

Abstract

BACKGROUND: Adenosine triphosphate-sensitive potassium (KATP) channels in brain are involved in neuroprotective mechanisms. Pharmacologic activation of these channels is seen as beneficial, but clinical exploitation by using classic K channel openers is hampered by their inability to cross the blood-brain barrier. This is different with the inhalational anesthetic xenon, which recently has been suggested to activate KATP channels; it partitions freely into the brain.
METHODS: To evaluate the type and mechanism of interaction of xenon with neuronal-type KATP channels, these channels, consisting of Kir6.2 pore-forming subunits and sulfonylurea receptor-1 regulatory subunits, were expressed in HEK293 cells and whole cell, and excised patch-clamp recordings were performed.
RESULTS: Xenon, in contrast to classic KATP channel openers, acted directly on the Kir6.2 subunit of the channel. It had no effect on the closely related, adenosine triphosphate (ATP)-regulated Kir1.1 channel and failed to activate an ATP-insensitive mutant version of Kir6.2. Furthermore, concentration-inhibition curves for ATP obtained from inside-out patches in the absence or presence of 80% xenon revealed that xenon reduced the sensitivity of the KATP channel to ATP. This was reflected in an approximately fourfold shift of the concentration causing half-maximal inhibition (IC50) from 26 +/- 4 to 96 +/- 6 microm.
CONCLUSIONS: Xenon represents a novel KATP channel opener that increases KATP currents independently of the sulfonylurea receptor-1 subunit by reducing ATP inhibition of the channel. Through this action and by its ability to readily partition across the blood-brain barrier, xenon has considerable potential in clinical settings of neuronal injury, including stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179498      PMCID: PMC2935677          DOI: 10.1097/ALN.0b013e3181cf894a

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  37 in total

1.  Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death.

Authors:  C Hernández-Sánchez; A S Basile; I Fedorova; H Arima; B Stannard; A M Fernandez; Y Ito; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Phospholipids as modulators of K(ATP) channels: distinct mechanisms for control of sensitivity to sulphonylureas, K(+) channel openers, and ATP.

Authors:  T Krauter; J P Ruppersberg; T Baukrowitz
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  Phospholipase C-linked receptors regulate the ATP-sensitive potassium channel by means of phosphatidylinositol 4,5-bisphosphate metabolism.

Authors:  L H Xie; M Horie; M Takano
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure.

Authors:  K Yamada; J J Ji; H Yuan; T Miki; S Sato; N Horimoto; T Shimizu; S Seino; N Inagaki
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

5.  Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells.

Authors:  C L Lawrence; P Proks; G C Rodrigo; P Jones; Y Hayabuchi; N B Standen; F M Ashcroft
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

6.  The carboxyl termini of K(ATP) channels bind nucleotides.

Authors:  Carlos G Vanoye; Gordon G MacGregor; Ke Dong; LieQi Tang; Alexandra S Buschmann; Amy E Hall; Ming Lu; Gerhard Giebisch; Steven C Hebert
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

7.  Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice.

Authors:  Masashi Suzuki; Norihito Sasaki; Takashi Miki; Naoya Sakamoto; Yuki Ohmoto-Sekine; Masaji Tamagawa; Susumu Seino; Eduardo Marbán; Haruaki Nakaya
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

8.  Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics.

Authors:  Richard J Gumina; Darko Pucar; Peter Bast; Denice M Hodgson; Christopher E Kurtz; Petras P Dzeja; Takashi Miki; Susumu Seino; Andre Terzic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-02-21       Impact factor: 4.733

9.  Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels.

Authors:  Carsten Bantel; Mervyn Maze; Stefan Trapp
Journal:  Anesthesiology       Date:  2009-05       Impact factor: 7.892

10.  Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery.

Authors:  Rolf Rossaint; Matthias Reyle-Hahn; Jochen Schulte Am Esch; Jens Scholz; Philippe Scherpereel; Benoit Vallet; Francesco Giunta; Monica Del Turco; Wilhelm Erdmann; Rob Tenbrinck; Alfons F Hammerle; Peter Nagele
Journal:  Anesthesiology       Date:  2003-01       Impact factor: 7.892

View more
  16 in total

Review 1.  [Current developments in xenon research. Importance for anesthesia and intensive care medicine].

Authors:  A Brücken; M Coburn; S Rex; R Rossaint; M Fries
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

Review 2.  [Neuroprotection by noble gases: New developments and insights].

Authors:  A V Fahlenkamp; R Rossaint; M Coburn
Journal:  Anaesthesist       Date:  2015-11       Impact factor: 1.041

Review 3.  Neuroprotective Properties of Xenon.

Authors:  Mervyn Maze; Timo Laitio
Journal:  Mol Neurobiol       Date:  2019-11-22       Impact factor: 5.590

4.  Application of medical gases in the field of neurobiology.

Authors:  Wenwu Liu; Nikan Khatibi; Aishwarya Sridharan; John H Zhang
Journal:  Med Gas Res       Date:  2011-06-27

5.  Antiapoptotic activity of argon and xenon.

Authors:  Sabrina Spaggiari; Oliver Kepp; Santiago Rello-Varona; Kariman Chaba; Sandy Adjemian; Jan Pype; Lorenzo Galluzzi; Marc Lemaire; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-07-16       Impact factor: 4.534

6.  Combination of therapeutic hypothermia and other neuroprotective strategies after an ischemic cerebral insult.

Authors:  Joline Goossens; Saïd Hachimi-Idrissi
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

7.  Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage.

Authors:  Yi-Feng Miao; Tao Peng; Melanie R Moody; Melvin E Klegerman; Jaroslaw Aronowski; James Grotta; David D McPherson; Hyunggun Kim; Shao-Ling Huang
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

8.  The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons.

Authors:  Jérémie Lavaur; Déborah Le Nogue; Marc Lemaire; Jan Pype; Géraldine Farjot; Etienne C Hirsch; Patrick P Michel
Journal:  J Neurochem       Date:  2017-05-16       Impact factor: 5.372

9.  Xenon in the treatment of panic disorder: an open label study.

Authors:  Alexander Dobrovolsky; Thomas E Ichim; Daqing Ma; Santosh Kesari; Vladimir Bogin
Journal:  J Transl Med       Date:  2017-06-13       Impact factor: 5.531

10.  Xenon impairs reconsolidation of fear memories in a rat model of post-traumatic stress disorder (PTSD).

Authors:  Edward G Meloni; Timothy E Gillis; Jasmine Manoukian; Marc J Kaufman
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.